CVS is opting against covering a twice-yearly injectable HIV prevention drug, drawing criticism from advocates who are ...

At the International AIDS Society meeting this year, a young woman from South Africa spoke. She is the first Black woman from ...

The owner of the U.S.' largest pharmacy benefit manager is declining to cover Gilead Sciences’ long-acting HIV prevention ...

Gilead Needs Insurers to Cover New HIV Prevention Shot. CVS Isn’t Paying. Executives at Gilead Sciences, the biotech behind a ...

By Deena Beasley (Reuters) -CVS Health, which runs the largest U.S. pharmacy benefit manager, will not add Gilead Sciences' ...

Gilead Sciences, Inc. (NASDAQ:GILD) is one of Goldman Sachs’ top healthcare stock picks. On July 10, the company announced it had reached an agreement with the Global Fund to Fight Aids ...

Gilead Sciences, Inc. (Nasdaq: GILD) today announced that Gilead researchers and collaborators will present new Phase 3 PURPOSE trial data at IAS 2025 showing that twice-yearly lenacapavir ...

(Reuters) -Gilead Sciences and the Global Fund to Fight AIDS, Tuberculosis and Malaria said on Wednesday they had finalized plans to supply a long-acting HIV prevention drug to low-income ...

Gilead Sciences, Inc. (NASDAQ:GILD), a U.S.-based biopharmaceutical company, researches and develops antiviral drugs for patients with HIV/AIDS, hepatitis B, hepatitis C, influenza, and COVID-19.

Kim Canady was only nine years old in 1996 when she faced the unimaginable loss of losing both her parents in the same year. At the time, she didn’t know her parents suffered HIV-related complications ...